This section is designed to provide important information regarding reimbursement, the IMBRUVICA® Dose Exchange Program, specialty pharmacies, and other product information.

Such information may be subject to continual change and interpretation. It is provided for informational purposes only and does not guarantee coverage or payment. It is always the provider's responsibility to determine and submit appropriate codes and modifiers based on the services rendered and the provider's medical judgment. Providers should contact the payer for coding and billing guidance.

IMBRUVICA® (ibrutinib) Diagnosis Codes


IMBRUVICA® is a kinase inhibitor indicated for the treatment of:

  • Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
  • Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.


CLL/SLL ICD-10 CM Codes in Detail

These are potential codes for consideration by you and your office.

CLL diagnosis codes2

C91.10Without mention of having achieved remission
C91.12In relapse

SLL diagnosis codes2

C83.00Unspecified site
C83.01Lymph nodes of head, face, and neck
C83.02Intrathoracic lymph nodes
C83.03Intra-abdominal lymph nodes
C83.04Lymph nodes of axilla and upper limb
C83.05Lymph nodes of inguinal region and lower limb
C83.06Intrapelvic lymph nodes
C83.08Lymph nodes of multiple sites
C83.09Extranodal and solid organ sites


1IMBRUVICA® (ibrutinib) Prescribing Information. 22023 CMS Code Descriptions in Tabular Order, Updated January 11, 2023.